title: Evaluating the immortal strand hypothesis in cancer stem cells: symmetric/self-renewal as the relevant surrogate marker of tumorigenicity.
abstract: Stem cells subserve repair functions for the lifetime of the organism but, as a consequence of this responsibility, are candidate cells for accumulating numerous genetic and/or epigenetic aberrations leading to malignant transformation. However, given the importance of this guardian role, stem cells likely harbor some process for maintaining their precious genetic code such as non-random segregation of chromatid strands as predicted by the Immortal Strand Hypothesis (ISH). Discerning such non-random chromosomal segregation and asymmetric cell division in normal or cancer stem cells has been complicated by methodological shortcomings but also by differing division kinetics amongst tissues and the likelihood that both asymmetric and symmetric cell divisions, dictated by local extrinsic factors, are operant in these cells. Recent data suggest that cancer stem cells demonstrate a higher incidence of symmetric versus asymmetric cell division with both daughter cells retaining self-renewal characteristics, a profile which may underlie poorly differentiated morphology and marked clonal diversity in tumors. Pathways and targets are beginning to emerge which may provide opportunities for preventing such a predilection in cancer stem cells and that will hopefully translate into new classes of chemotherapeutics in oncology. Thus, although the existence of the ISH remains controversial, the shift of cell division dynamics to symmetric random chromosome segregation/self-renewal, which would negate any likelihood of template strand retention, appears to be a surrogate marker for the presence of highly malignant tumorigenic cell populations.
authors: Vertex Pharmaceuticals Incorporated, Department of Integrated Biology, 50 Northern Avenue Boston, MA 02210, United States. Electronic address: raymond_winquist@vrtx.com.
authors: Raymond J
authors: RJ
authors: Winquist
authors: Vertex Pharmaceuticals Incorporated, Department of Integrated Biology, 50 Northern Avenue Boston, MA 02210, United States.
authors: Amy B
authors: AB
authors: Hall
authors: Vertex Pharmaceuticals Incorporated, Department of Integrated Biology, 50 Northern Avenue Boston, MA 02210, United States.
authors: Brenda K
authors: BK
authors: Eustace
authors: Vertex Pharmaceuticals Incorporated, Department of Integrated Biology, 50 Northern Avenue Boston, MA 02210, United States.
authors: Brinley F
authors: BF
authors: Furey
mesh_terms: D000818:Animals; D015415:Biomarkers; D063646:Carcinogenesis; D049109:Cell Proliferation; D004261:DNA Replication; D006801:Humans; D014411:Neoplastic Stem Cells / Q000502:physiology*
chemical_list: D015415:Biomarkers
keywords: Asymmetric cell division; Cancer; Cancer stem cells; Immortal Strand Hypothesis; Symmetric cell division; Tumorigenicity